| Bioactivity | Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation. | |||||||||
| Invitro | Carbacyclin is an agonist of prostacyclin (PGI2) receptor[1]. Carbacyclin acts as an inhibitor of platelet aggregation induced by ADP or collagen in vitro[2]. Carbacyclin is a PGI2 analogue, activates CPT-1 mRNA expression through PPARδ, independent of the IP receptor signaling pathway. Carbacyclin (0.02 μM to 20 μM) activates the IP receptor signaling pathway via PKA, and such an effect is inhibited by H-89, a PKA inhibitor. Carbacyclin (0.02-80 μM) increases PPRE promoter activity via PPARδ independent of the IP receptor signaling pathway in cardiomyocytes[3]. | |||||||||
| In Vivo | Carbacyclin is 0.03 times as active as prostacyclin on inhibiting platelet aggregation in human, dog or rabbit plasma[2]. Carbacyclin (100 μg, i.p.) induces CPT-1 mRNA expression in murine heart[3]. | |||||||||
| Name | Carbacyclin | |||||||||
| CAS | 69552-46-1 | |||||||||
| Formula | C21H34O4 | |||||||||
| Molar Mass | 350.49 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Takasuka M, et al. FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor agonist (U-46619), prostaglandin (PG)E2, PGD2, PGF2 alpha, prostacyclin receptor agonist (carbacyclin), and their related compounds in dilute CCl4 soluti [2]. Whittle BJ, et al. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19(4):605-27. [3]. Kuroda T, et al. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway. J Mol Cell Cardiol. 2007 Jul;43(1):54-62. |